Open an account

Ascendis Pharma A/S

ASND · NASDAQ

$243.37+$0.38 (+0.16%)TodayMarket closed ·
Prev close $242.99

About ASND

Ascendis Pharma A/S is a DK-based company operating in Biotechnology industry. Ascendis Pharma A/S is a Denmark‑based biopharmaceutical company operating within the life sciences and biotechnology sector. The firm scope of activity includes discovery, development, and commercialization of innovative therapies for rare diseases and serious chronic conditions with significant unmet medical needs where a clinically validated parent drug or pathway is suitable to company technologies. Ascendis Pharma A/S focuses on the endocrinology area and has a pipeline of three independent rare disease product candidates, such as Growth Hormone Deficiency (GHD), Hypoparathyroidism and Achondroplasia. The second therapeutic area is oncology, where the company focuses immunotherapy to targeted therapies.

Employees
1,189
Headquarters
Hellerup
Listed
Jan 28, 2015
Sector
Health Care
Industry
Biotechnology
Website
ascendispharma.dk

ASND key statistics

Market cap
15.16B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
767.03K
Volume
575.42K
Open price
$242.00
High today
$244.58
Low today
$240.79
52 Week high
$282.15
52 Week low
$188.07

Ascendis Pharma A/S (ASND) at a glance

As of Oct 23, 2026, Ascendis Pharma A/S (ASND) shares are priced at $243.37, giving the company a market cap of 15.16B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $240.79 and $244.58. The current price is 1.1% above the day's low and 0.5% below its high.

Volume so far is 575.42K shares, below the average of 767.03K shares a day.

Over the past year Ascendis Pharma A/S has ranged from $188.07 to $282.15, and now sits 59% of the way up that range.

Ascendis Pharma A/S met or beat analyst EPS estimates in 3 of the last 8 quarters. In Q2 FY26 it reported $0.72 per share against an estimate of $1.41.

The average analyst price target is $319.29, 31.2% above the current price, from 18 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 18 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 24 analystsAvg $319.29
Low
$271.69
Now
$243.37
High
$378.00

ASND earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 3 of the last 8 quarters, by 29.1% on average.

  1. Q3 FY24: reported -$1.72 per share against an estimate of -$1.77
  2. Q4 FY24: reported -$0.64 per share against an estimate of -$0.9771
  3. Q1 FY25: reported -$1.58 per share against an estimate of -$1.52
  4. Q2 FY25: reported -$0.64 per share against an estimate of -$1.27
  5. Q3 FY25: reported -$1.00 per share against an estimate of -$0.2244
  6. Q4 FY25: reported -$0.55 per share against an estimate of -$0.0459
  7. Q1 FY26: reported -$0.77 per share against an estimate of $0.2075
  8. Q2 FY26: reported $0.72 per share against an estimate of $1.41

ASND news

  • Vandana Singh

    Why Is Ascendis Pharma Stock Trading Lower on Tuesday?

  • Piero Cingari

    10-Year Yield Tops 5%, Oil Storms Past $105: Stock Market Today

  • Vandana Singh

    Ascendis Pharma Says Growth Drug Shows Benefits in Infants

  • Press releaseGlobe Newswire

    Ascendis Pharma to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

  • Avi Kapoor

    Crude Oil Gains Over 2%; US Dallas Fed Manufacturing Index Surges In August

  • Vandana Singh

    Biomarin, Ascendis Reach Mutually Beneficial Agreement Ending Global Patent Disputes

  • Full Transcript: Ascendis Pharma Q2 2026 Earnings Call

  • Press releaseGlobe Newswire

    Ascendis Pharma Reports Second Quarter 2026 Financial Results

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.